China Shineway Pharmaceutical Group Limited (C1S) — Working Capital to Net Assets Ratio
China Shineway Pharmaceutical Group Limited (C1S) has a Working Capital to Net Assets ratio of 84.3% as of December 2025. Working capital of €6.79 Billion (current assets of €9.30 Billion minus current liabilities of €2.51 Billion) is measured against net assets of €8.06 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See China Shineway Pharmaceutical Group Limi (C1S) net asset quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
China Shineway Pharmaceutical Group Limited Working Capital to Net Assets (2013–2025)
This chart shows how China Shineway Pharmaceutical Group Limited's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of December 2025, the ratio stands at 84.3%, reflecting working capital of €6.79 Billion against net assets of €8.06 Billion EUR. Check China Shineway Pharmaceutical Group Limi tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for China Shineway Pharmaceutical Group Limited (2013–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for China Shineway Pharmaceutical Group Limited from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see China Shineway Pharmaceutical Group Limi market cap and net worth.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 84.3% | €6.79 Billion | €8.06 Billion | €9.30 Billion | €2.51 Billion | ▲ +1.9 pp |
| 2024 | 82.3% | €6.15 Billion | €7.47 Billion | €8.60 Billion | €2.45 Billion | ▲ +1.0 pp |
| 2023 | 81.3% | €5.72 Billion | €7.03 Billion | €8.15 Billion | €2.43 Billion | ▲ +1.2 pp |
| 2022 | 80.2% | €5.12 Billion | €6.38 Billion | €6.78 Billion | €1.67 Billion | ▲ +2.2 pp |
| 2021 | 78.0% | €4.60 Billion | €5.90 Billion | €5.70 Billion | €1.10 Billion | ▲ +3.3 pp |
| 2020 | 74.6% | €4.32 Billion | €5.79 Billion | €5.52 Billion | €1.19 Billion | ▲ +5.0 pp |
| 2019 | 69.7% | €4.03 Billion | €5.78 Billion | €5.20 Billion | €1.18 Billion | ▲ +2.5 pp |
| 2018 | 67.2% | €3.87 Billion | €5.77 Billion | €4.65 Billion | €780.27 Million | ▲ +1.0 pp |
| 2017 | 66.2% | €3.85 Billion | €5.82 Billion | €4.56 Billion | €709.29 Million | ▲ +2.6 pp |
| 2016 | 63.6% | €3.58 Billion | €5.63 Billion | €4.25 Billion | €673.06 Million | ▲ +4.3 pp |
| 2015 | 59.3% | €3.14 Billion | €5.30 Billion | €3.84 Billion | €701.61 Million | ▼ -3.3 pp |
| 2014 | 62.6% | €3.06 Billion | €4.89 Billion | €3.95 Billion | €885.99 Million | ▲ +1.7 pp |
| 2013 | 60.9% | €2.70 Billion | €4.43 Billion | €3.88 Billion | €1.18 Billion | — |